Skip to main content
ISOP ACoP 2025 Annual Conference Main banner
ViewAttendees 1
Symposium

General Pharmacometrics

C4C - Advances in Mathematical and Computational Modeling for Radiopharmaceutical Therapies

Tuesday, October 21, 2025
9:00 AM - 10:30 AM MDT
Location: Red Rock 8/9

Disclosure(s):
Francois p. Combes, PhD PharmD: No relevant disclosure to display
Hunter Stephens, PhD: No financial relationships to disclose
Moses Wilks, PhD: No financial relationships to disclose
Karthik Lingineni, PhD: No financial relationships to disclose
Kuangyu Shi, PhD: No relevant disclosure to display
Fariba Khanshan, PhD: No financial relationships to disclose

Description of session (include background & scientific importance): Radiopharmaceutical therapy (RPT) utilizes targeted molecules conjugated with alpha or beta emitters (e.g., 177Lu, 225Ac) to treat various cancers. Exposure of cancer cells to radioactivity leads to DNA damage that can overwhelm the cancer cell’s repair capabilities. In RPT, radiation is delivered systemically or locally via molecules that selectively bind to cancer cells or accumulate by physiological mechanisms. This targeted approach enables the destruction of cancer cells while sparing healthy tissue. These molecules can also be tagged with radioisotopes (e.g., 18F, 68Ga) that can be imaged using techniques like a PET scan to visualize the location and distribution of the cancer cells. Major pharmaceutical companies have expanded their portfolios by acquiring radiopharmaceutical firms.

Current RPT guidelines, however, typically follow a “one-size-fits-all” approach, where patients receive the same amount of radioactivity per cycle. This overlooks individual variations in radiopharmacokinetics, radiation biology, and immune factors that can affect treatment outcomes. To optimize RPT, more personalized strategies are needed.
Modeling techniques have emerged as key tools in this effort, helping to predict the behavior of radiopharmaceuticals in patients. By integrating pharmacokinetics, dosimetry, and biological response models, these modeling approaches can provide insights into dose distribution, efficacy, and potential toxicity. Techniques like physiologically-based radiopharmacokinetic modeling or digital twin technology are being used to analyze RPTs. These efforts are crucial for optimizing therapies and ensuring safe, effective clinical trials. To advance this field, we are hosting a session with experts from academia and industry to explore how computational modeling approaches can optimize RPTs.

SPONSORED BY: NOVARTIS

Learning Objectives:

  • Upon completion, participants will be able to: • Demonstrate foundational knowledge on the principles, techniques, and advances in radiopharmaceutical imaging and therapy. • Understand the applications of modeling/simulation approaches to personalize radiopharmaceutical therapies. • Reflect on real-world case studies of significant advancements from an industry, academic and regulatory perspective. • Recognize the challenges and future directions of this rapidly developing field. • Engage in interdisciplinary dialogue and facilitate cross-disciplinary discussions between researchers, clinicians, and modeling professionals from industry, aimed at fostering collaboration and advancing the field.

Presentations:

  • 9:00 AM - 9:22 AM MDT
    Predictive Dosimetry and Dose Personalization in Targeted Radiopharmaceutical Therapy

    Speaker: Moses Wilks, PhD (he/him/his) – Yale University

  • 9:22 AM - 9:45 AM MDT
    An Integrated model Lu-PSMA-617 dose, tumor dosimetry, PSA and OS to enable future study design

    Speaker: Karthik Lingineni, PhD – Novartis Pharmaceutical Corporation

  • 9:45 AM - 10:07 AM MDT
    Digital Twins for Personalized Radiopharmaceutical Therapy

    Speaker: Kuangyu Shi, PhD (he/him/his) – University of Bern

  • 10:07 AM - 10:30 AM MDT
    Reduced dosimetry using NLME

    Speaker: Fariba Khanshan, PhD (she/her/hers) – AstraZeneca/Novartis